We reviewed the results of treatment in 52 patients with hypopharyngeal carcinoma who underwent radical radiation therapy using a two-fractionation scheme -conventional fractionation (CF) and accelerated hyperfractionation (AHF) -in order to evaluate the impact of the fractionation scheme on prognosis. The 5-year survival rate for the 52 patients was 19.5%, and a significantly better rate was obtained with AHF (44.4%) than with CF (12.4%). Of 27 patients who showed a complete response (CR), a higher CR rate (61%) was achieved with AHF than with CF (47%). A similar trend was also observed for T3 and T4 tumors (55% with AHF vs. 36% with CF). Multivariate analysis demonstrated that neck node status was a significant factor relat-/ ed to local control, and that local response and the fractionation scheme employed were significant prognostic factors for survival. The recurrence rate and recurrence within the radiation field in the AHF group was lower than in the CF group (27% vs. 50%), although the time to recurrence in the two groups did not differ greatly. Voice preservation was achieved in 20% of the patients. Considering the better survival and local control rate compared with conventional fractionation, accelerated hyperfractionation seems a preferable treatment for hypopharyngeal carcinoma.
Introduction
The prognosis of hypopharyngeal carcinoma is poor due to the high incidence of patients with advanced disease because of extensive involvement of cervical lymph nodes at initial presentation. Surgery with or without radiation therapy provides a better prognosis than radiation therapy alone, 1 ' 2) but the latter treatment is still used in patients for whom surgery is inadvisable due to medical problems or old age, or who have refused an operation. Radiation therapy has been considered the treatment of choice for early-stage disease, allowing satisfactory local control with voice preservation. 3 ' On the Received: October 16, 1995 Accepted: February 14, 1996 For reprints and all correspondence: Tetsuo Akimoto, Department of Radiology and Radiation Oncology, Gunma University School of Medicine, 39-22, Showa-machi 3-chome, Maebashi, Gunma 371 other hand, the prognosis for patients with advanced disease is poor because of the poor local control rate with radiation therapy and the occurrence of distant metastasis as well as the low salvage rate with surgery. 4 
'
In recent years, hyperfractionated radiation therapy has been introduced in order to reduce late complications and improve local control. 5 ' The biological basis of altered fractionation has been discussed in detail by Withers, 61 and improved results have been reported for head and neck cancers treated by hyper-or accelerated fractionation. 7 ' 8) In our hospital, hyperfractionation was first introduced in 1987, and accelerated hyperfractionation, which uses a larger dose per day than hyperfractionation and can substitute for conventional fractionation, has been used for treatment of hypopharyngeal carcinoma. We reviewed the results of treatment for hypopharyngeal carcinoma using radiation therapy with curative intent, and retrospectively analyzed the prognostic factors and the impact of differences in the fractionation scheme on prognosis.
Materials and Methods
Between 1971 and 1993, 67 patients with hypopharyngeal carcinoma were treated by radiation therapy with and without surgery. Patients treated preoperatively with palliative intent were excluded, and 52 patients who received potentially curative radical radiation therapy were analyzed. The patients' ages ranged from 41 to 87 yr with a median of 65 yr, and 37 were male and 15 female. All the tumors were biopsy-proven squamous cell carcinomas. The patients' characteristics are shown in Table I .
Radiation therapy was delivered by high-energy photons with an energy of 10 MV, or by 6 MV x-rays. All patients were treated using two lateral parallel opposing fields encompassing the primary tumor and cervical lymph nodes, and boosted for the primary lesion with localized fields after 40-50 Gy. The fractionation scheme consisted of two types: 1) conventional fractionation (CF): 34 patients, 2.0 Gy per fraction, 5 days per week, and 2) accelerated hyper fractionation (AHF): 18 patients, twice a day, 1.6 Gy per fraction at 6-h intervals. One patient treated with a fraction dose of 1.5 Gy was included in this group. The average age of patients treated with the two fractionation schemes was 64 yr in the CF group and 67 in the AHF group. For AHF, the patients were given a rest period of 2 weeks after 38.4 Gy to recover from the acute mucosal reaction. Altogether they received a total dose of 64 Gy. After the introduction of AHF in 1987, most patients with hypopharyngeal carcinoma were treated with AHF as a standard procedure. In the early period of AHF use, some patients received over 70 Gy with the same fraction size. The total dose ranged from 56 to 76.8 Gy with a mean dose of 65 Gy, and the mean total dose for the two fractionation schemes did not differ significantly, being 66 Gy in the CF group and 68.4 Gy in the AHF group. The median overall treatment time was 59 days (range: 48-67 days) in the CF group and 47 days (range: 38-59 days) in the AHF group. Prolongation of the planned split time in the AHF group was recognized in half of the patients, and the median split time was 17 days (range: 9-28 days).
Salvage surgery was performed in only 11 patients with residual or recurrent tumors because of the poor medical conditions or unresectable nature of the tumor; six of these patients were in the AHF group and the others were in the CF group. Local response was determined on the basis of clinical and endoscopic findings or biopsy at the primary site.
All patients were followed up either until death or for a minimum of two years, and patients who were lost to follow-up were excluded from the study. The survival probability of the patients was calculated by the Kaplan-Meier method, 9 ' and a comparison of survival in different subgroups was made using the generalized Wilcoxon test; the chi-squared test was used to assess differences among proportions. 10 ' The factors that were thought to influence survival and local control were analyzed by multivariate analysis with Cox's proportional hazards model and logistic regression analysis.
"

Results
Local Control and Recurrence
Of 52 patients, 27 (52%) achieved a complete response (CR) with radiation therapy. The T-stage distribution of CR patients was four in Tl (67%), six in T2 (67%), 14 in T3 (39%) and three in T4 (33%). The CR rate according to fractionation scheme was 11 of 18 (61%) treated by AHF and 16 of 34 (47%) treated by CF. In patients with T3 and T4 tumors, the CR rate for the AHF group (six of 11 patients: 55%) was better than for the CF group (10 of 26 patients: 36%), but there was no significant difference in local control rates between the two fractionation groups in patients with N2 and N3 disease (AHF group: 33% vs. CF group: 40%). The overall treatment time and duration of split time for the AHF group indicated that neither factor had a significant impact on the local control rate, i.e., 44% of nine patients with a split time of > 14 days versus 78% of nine with ^ 14 days, and 50% of 12 patients with an overall treatment time of >43 days versus six with ^43 days. In 27 patients with CR, recurrence was noted in 16, of whom 6 had been treated with AHF and 10 with CF. Only two patients treated by AHF, who had cervical lymph node recurrence and local recurrence, were salvaged by surgery. Intra-radiation field recurrence was seen in eight of 16 patients (50%) in the CF group and three of 11 (27%) in the AHF group. The time to recurrence was less than two years in all but one patient. The median time to recurrence was six months in the CF group and 11 months in the AHF group, and the recurrence rate for patients with CR in both fractionation groups at two years was 63% in the CF group and 45% in the AHF group. Only three patients with non-CR survived; two were salvaged by surgery and one was not treated.
Of 11 patients for whom salvage surgery was performed after radiation therapy (at recurrence in four with CR, the others showing non-CR), only five survived. Four of these were treated by AHF. Of eight patients for whom salvage surgery was performed because of residual tumor, only two treated by AHF survived. Voice preservation was achieved in 11 patients (20%).
Survival
The 3-and 5-year actuarial survival rates for all patients were 22.3% and 19.5%, respectively. The 5-year survival rate according to stage was 100% for stage I, 37.5% for stage II, 20.0% for stage III and 14.3% for stage IV (Fig. 1) , and 50%, 27.8%, 8.2% and 0% for Tl-4, respectively. However, these factors showed no statistically significant difference, because most patients had a high Tstage and advanced disease. With regard to cervical lymph node status, an improved 5^year survival rate was recognized in patients without neck node metastasis (39.1%) compared with those showing neck node metastasis (15.6%), although the difference was not significant. There was also no significant difference between the primary tumor site, the subclassifications of N1-N3 and the level of neck nodes. In contrast, there was a significant difference (P<0.05) in the 5-year survival rate between the group given CF (12.4%) and that given AHF (44.4%) (Fig. 2) . Furthermore, patients with CR showed a significantly better survival rate (34.6%) than those with non-CR (9.6%) (P<0.05, Fig. 3 ).
Multivariate Analysis
Several prognostic variables were correlated with the outcome. Evaluating from a 95% confidence interval and relative risk, neck node status was a statistically significant factor for local control (Table II) and local response, i.e., CR or non-CR, and the fractionation scheme employed was statistically significant for survival (Table III) . Other factors did not significantly affect survival or local control. The relative survival risk for patients treated with CF was estimated to be about 2.5 times higher than that of patients treated with AHF, and was about twice as high for non-CR patients as for CR patients. 
Complications
Ninety-four percent and 95% of the patients in the two groups were able to complete the planned treatment. An acute mucosal reaction was observed in all patients, and almost half of the CF group needed a rest period during treatment. Acute reactions tended to be more severe in the AHF group, and this caused prolongation of the planned 2-week rest period, although the planned total dose was successfully delivered. No late effect such as bone necrosis has yet occurred at the time of writing.
Discussion
The present study involved a retrospective analysis of the results of radiation therapy for hypopharyngeal carcinoma, which has one of the poorest prognoses among head and neck cancers because of its high incidence of loco-regional advanced disease.
l213) The main aim was to study the prognostic factors and the impact of the CF and AHF fractionation schemes of radiation therapy on loco-regional control and survival. In the early stages of the disease, satisfactory results have been obtained with CF.
M) Ahmad et al. l5 ) reported a local control rate of 46.2% for T2, in contrast to 0% for T4 tumors. The results of loco-regional control in our study demonstrated that the CR rate for the AHF group was better than for the CF group, but multivariate analysis revealed that the most significant factor for local control was the subclassification of neck nodes (N0-N3), whereas other factors, including the fractionation scheme employed, T-factor and primary site, did not reach statistical significance. As to relative risk for local control in patients with N3, this was about eight times higher than for those without neck node involvement. This may reflect the difficulty in controlling cervical lymph node involvement even by AHF. Wang et c/.
16il7) reported that a better local control rate than that for CF was obtained by AHF in head and neck cancer, and that the local control rate for patients with advanced local disease and neck node involvement was higher after AHF than after CF. As for why AHF did not provide a better control rate than CF for patients with N2-N3 disease, we considered the fact that other reports on the efficacy of AHF have included various primary site cancers, such as oropharyngeal cancer and laryngeal caner.
18
- 19) Radiosensitivity and the response to radiation therapy differ according to the degree of histological differentiation, even for the same histological type, i.e. a poorly differentiated tumor tends to show a better response to radiation. In comparison with other head and neck cancer, 20 ' hypopharyngeal carcinoma is often well differentiated squamous cell carcinoma. This may account for the above results.
In contrast to the results for local control, the most striking difference for prognosis was observed between the two fractionation schemes, that is, superior results were obtained in the AHF group. Multivariate analysis showed that the fractionation scheme and local response had a positive impact on survival. We consider that the recurrence rate and pattern of failure might have some relation to the stronger impact of the fractionation scheme on survival than on local control. The lower recurrence rate at two years in the AHF group suggests that persistent local control is also better with AHF, although AHF has little effect prolonging the time to recurrence. The recurrence patterns in relation to the radiation field were also different, that is, the rate of recurrence within the radiation field was lower in the AHF group than in the CF group. This may have been partly responsible for the better salvage rate in the AHF group. Also in patients with non-CR, tumor shrinkage caused by the AHF may have a favorable influence on resectability in salvage surgery.
In this study, more patients with a short followup period were included in the AHF group than in the CF group due to the late introduction of the hyperfractionation scheme. However, a minimum 2-year follow-up period is considered necessary for evaluating the impact on local control rate and prognosis, because hypopharyngeal carcinoma has a poor prognosis and recurrence tends to occur within 2 years. Marks et al. 2i) reported that 80-90% of recurrences were observed in the first 2 years.
The fractionation scheme used in this study was based on the regimen of Wang et al. with a fraction dose of 1.6 Gy twice a day with a 6-h interfraction interval. The main reason for the better results with AHF is believed to be the delivery of a large dose of radiation within a shorter treatment period, since head and neck cancer is considered to behave like an acutely responding tissue. A shortened overall treatment time leads to a reduction of tumor cell repopulation during the treatment course. In this study, a better local control rate was obtained among the patients in the AHF group with shorter overall treatment and split times. Taking into account the data of Wang et al. l6) and Radiation Therapy Oncology Group (RTOG), 22>23) the optimal fraction dose, fractions per day and interfraction interval for hyperfractionation have all been established, but there are still an insufficient number of clinical reports to verify the effectiveness of AHF. This study, limited to patients with hypopharyngeal carcinoma, demonstrated that this approach is well tolerated in spite of the relatively larger radiation field than that for other head and neck cancers such as laryngeal cancer, although the follow-up period was too short for-evaluation of late toxicity.
In conclusion, this study has demonstrated the efficacy of AHF for hypopharyngeal carcinoma, offering a better survival rate than that with CF. In the early stages of disease, or in patients without cervical lymph node metastasis, AHF is considered to be the treatment of choice, although our study failed to show any apparent improvement in response because AHF was associated with problems related to the management of patients with extensive cervical lymph node involvement. In addition to further study of the use of this regimen in a larger number of patients, combined modalities including surgery for cervical lymph node metastasis or chemotherapy, and also modification of the regimen, may be necessary for selected patients in order to improve the prognosis for those with advanced disease.
